

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 67072

Title: The paradox role of interleukin-33/suppressor of tumorigenicity 2 in colorectal carcinogenesis, progress and therapeutic potential

Reviewer's code: 05048167

Position: Editorial Board

Academic degree: PhD

Professional title: Senior Scientist

Reviewer's Country/Territory: Germany

Author's Country/Territory: China

Manuscript submission date: 2021-04-26

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-04-26 09:09

Reviewer performed review: 2021-04-27 14:10

Review time: 1 Day and 5 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Dear Editor, Dear Authors, It is promising to have a nice structured review article to summarize the role of IL-33 / ST2 in colorectal cancer prevention, carcinogenesis, progress and their therapeutic potential based on a number of update evidence and studies. However, there are still some major points, which have to be further concerned.

1. It is suggested to incorporate better graphic figures to illustrate both the structure of IL-33 and its ligand ST2 as well as the role of IL-33 / ST2 in CRC carcinogenesis and progression if applicable. For the therapeutic potentials, a comprehensive table to sum up the therapeutic strategies targeting IL-33 / ST2 will be more informative. 2. It is highly important to ask the author to check all the references cited in the manuscript properly. For instance: #In particular, it is worth mentioning that several risk factors are related CRC development, including lack of exercise, smoking, red meat and alcohol consumption [3, 4]. Reference 4 doesn't mention this point. #Combining radiation with conventional chemotherapy can exacerbate mucositis, leading to chemotherapeutic dose reductions or inevitable cessation of such treatments [49, 50]. It is rather hard to find the correlated description in the reference 49 and 50. 3. In the title there is a focus on colorectal carcinogenesis, progress....but in the content, there is only a part for IL-33 / ST2 and CRC progression, the structure need to be better organized. 4. There are already IL-33 antibody clinical trials, for instance, SAR440340 (Anti-IL-33 mAb) or other blockade strategies could be further discussed in the part of: Diversified therapeutics based on IL-33 / ST2 signaling in CRC. 5. The potential role of IL-33 in regulating tumor initiating cells has been reported, as well as the impact on stem cell- niche interactions. (Taniguchi et al Science 2021), this new highlight could be further integrated into the review, linking to CRC prospects. Minor pointes: 1. There are still some mistakes about language and typos, the authors are suggested to optimize the manuscript

completely The expression like: ‘Generally speaking’, ‘type-II diabetes’, ‘Recent research progress seem to provide’ in the context, has to be avoided 2. Be consistent with the space before the citation, some have, some did not have, please update that accordingly.

3. A summary of abbreviations will be appreciated